21. Mitochondrial disease Clinical trials / Disease details

Clinical trials : 33 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643249 (ClinicalTrials.gov)	November 10, 2020	13/11/2020	Drug-drug Interaction Study of KL1333 in Healthy Subjects	A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects	Mitochondrial Disease	Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide	Abliva AB	NULL	Completed	18 Years	65 Years	All	14	Phase 1	United Kingdom
2	NCT03888716 (ClinicalTrials.gov)	March 18, 2019	19/3/2019	A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease	A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease	Mitochondrial Diseases;Mitochondrial Respiratory Chain Deficiencies;MELAS Syndrome;Mitochondrial Myopathies	Drug: KL1333;Drug: Placebo Oral Tablet	Abliva AB	NULL	Completed	18 Years	75 Years	All	72	Phase 1	United Kingdom